Psychedelics and mental health: reimagining care through science, insight, and compassion.
Front Pharmacol September 3, 2025 Georgios Mikellides, Marios Kyriazis 3 citations
Psychedelic compounds are being revisited as facilitators of profound psychological experiences with therapeutic implications for mental health conditions, particularly treatment-resistant depression and PTSD. Psilocybin has shown significant efficacy in reducing depressive symptoms in randomized controlled trials, though one study found no significant difference between psilocybin and escitalopram on the primary outcome. MDMA-assisted therapy reduced PTSD symptoms with a large effect size in a Phase 3 trial, but the FDA declined approval in 2024 due to methodological concerns. Psychedelics promote neuroplasticity and alter brain network connectivity, enabling emotional catharsis and existential re-evaluation. MDMA-assisted therapy was found cost-effective for PTSD, with net healthcare savings of $132.9 million per 1,000 patients. The article advocates for balanced, evidence-based integration into psychiatric care, emphasizing the need for rigorous trials, therapist training, and ethical protocols.